GMR Solutions Q3 2026 earnings
Revenue and net income grew in Q3, with net income up 81.7% to $135.6 million, despite weather-related pressure and inflationary costs.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $1,595.6M | +5.9% | +7.0% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.56 | +700.0% | +314.3% | Ex. 99.1, income statement |
| EPS (adjusted) | $0.57 | +714.3% | +321.4% | Ex. 99.1, income statement |
| Net income | $135.6M | +81.7% | +481.0% | Ex. 99.1, income statement |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin 13.6% (prior 13.8%, change -0.2 pp)
- Operating expenses $1,334.1M (+3.3% YoY)
- One-offs in the quarter Stock-based compensation: $1.6M (vs $5.8M YoY); Professional fees and other expenses for non-recurring matters: $11.5M (vs $4.5M YoY); Debt refinancing fees paid to (received from) third parties: $3.4M (vs $39.1M YoY); Loss on debt extinguishment: $5.7M; Impairment of assets held for sale and other investments: $14.1M (Nine Months); (Gain) loss on divestiture of businesses: $3.8M (Nine Months)
- Effective tax rate 43.4% (prior 28.5%, year-to-date 32.7%)
- Non-GAAP bridge Adds back management fees, stock-based compensation, professional fees for non-recurring matters, and debt refinancing fees.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Revenue per transport | Not stated | Not stated | Not stated | Not stated |
| Critical care intervention frequency | Every 87 seconds | Every 88 seconds | Not stated | Faster |
| Patient encounters | Not stated | Not stated | Not stated | Not stated |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Net revenue | $5.9B - $6.05B | $5.89B - $6.18B | -0.1% - -2.1% |
| Adjusted EBITDA | $1.135B - $1.195B | $1.135B - $1.195B | No change |
| Cash used for net capital expenditures and aircraft financing as a percent of net revenue | 5.2% - 5.4% | 5.1% - 5.3% | +0.1% - +0.1 pp |
What drove it
- Revenue story Revenue increased 5.9% to $1,595.6 million, driven by growth in core emergent services and Nurse Navigation, despite weather-related pressure on flight activity.
- EPS story EPS growth was driven by higher net income, improved operating margins, and a lower tax rate, partially offset by higher interest expense.
- One-off check Stock-based compensation decreased significantly year-over-year to $1.6 million, while debt refinancing fees decreased to $3.4 million.
The good
- Revenue growth of 5.9% despite weather-related pressure and inflationary costs.
- Net income increased 81.7% to $135.6 million.
- Adjusted EBITDA increased 4.2% to $356.6 million.
The bad
- Operating expenses increased 3.3% year-over-year.
- Interest expense increased 36.5% year-over-year to $68.1 million.
- Weather-related pressure on flight activity and higher fuel costs.
The ugly
- none
Open questions
- The filing does not disclose the specific revenue per transport metric.
- The filing does not disclose the specific patient encounter count.
Full release
GMR Solutions (GMRS) earnings release, November 9, 2026
GMR Solutions Inc. Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Updated Full Year 2026 Guidance
LEWISVILLE, Texas (November 9, 2026) — GMR Solutions Inc. (“GMR” or the “Company”) (NYSE: GMRS), the nation’s largest provider of emergency medical services (“EMS”), today announced financial results for the three and nine months ended September 30, 2026, and updated its full year 2026 financial guidance.
“The third quarter showcased the resiliency that is inherent in GMR’s scale, national footprint, and integrated model,” said Nick Loporcaro, Chairman and Chief Executive Officer. “Our ability to serve patients across a broad range of operations and geographies helped us navigate weather-related constraints and other external pressures while continuing to grow our core emergent services. Combined with the momentum we are seeing in Nurse Navigation and new market growth, these results reinforce our confidence in the strength of our platform and opportunities ahead.”
“We delivered strong financial performance in the third quarter, with revenue increasing 5.9% to $1,595.6 million, and net income increasing 81.7% to $135.6 million, despite weather-related pressure on flight activity, higher fuel and other inflationary costs, and the anticipated shift in payor mix,” said Brian Tierney, Chief Financial Officer. “Growth in our core emergent services, continued improvement in revenue per transport and disciplined cost management helped us absorb these headwinds while continuing to invest in the business and strengthen our financial position.”
Third Quarter 2026 Financial Highlights
¹
Key Financials
Business Metrics
²
Full Year 2026 Financial Guidance
GMR is updating the following guidance for the full year 2026:
Webcast and Conference Call Details
The Company will host a conference call tomorrow, November 10, 2026, at 8:00 a.m. Eastern Time. Investors can access the live call by joining the following link https://events.q4inc.com/attendee/164439003.
An archived webcast of the event will be available on the “Events & Presentations” section of the GMR website at https://investors.globalmedicalresponse.com/. The Company has posted supplemental information on the results that it will reference during the conference call. The supplemental information can be found under the “Financials” tab on the Company’s investor relations page. Following the live event, replays will be available via webcast for one year at https://investors.globalmedicalresponse.com/.
About Global Medical Response
GMR is the nation’s largest provider of EMS, delivering EMS and other essential out-of-hospital care in rural and urban communities that represent more than 60% of the U.S. population. As the only national, fully integrated, air and ground EMS provider, GMR operates in approximately 1,400 counties across the country. A recognized innovator, GMR develops new solutions to meet evolving industry needs and expand access to high-quality care. With approximately 34,000 team members, GMR supports roughly 5.5 million patient encounters annually and performs a critical care intervention every 87 seconds. Its family of solutions includes ambulance EMS provider American Medical Response, as well as multiple air EMS organizations including Air Evac Lifeteam, REACH Air Medical Services, Guardian Flight, Med-Trans Corporation, and AirMed International.
We may use our website (www.globalmedicalresponse.com), Facebook page (www.facebook.com/GlobalMedicalResponse), X (Twitter) (www.x.com/GMR_Social), LinkedIn (www.linkedin.com/company/Global-Medical-Response), and Instagram (www.instagram.com/Global_Medical_Response), accounts as channels of distribution of company information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, Securities and Exchange Commission (“SEC”) filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the “Investor Email Alerts” section of our website at https://investors.globalmedicalresponse.com/resources/investor-email-alerts/default.aspx. The contents of our website, any alerts and social media channels are not, however, a part of this press release.
Financial statements
Income Statement
Three Months Ended — Key Financials (in thousands)
| Three Months Ended – September 30, – 2026 – (Unaudited) | Three Months Ended – September 30, – 2025 – (Unaudited) | % | Nine Months Ended – September 30, – 2026 – (Unaudited) | Nine Months Ended – September 30, – 2025 – (Unaudited) | % | |
|---|---|---|---|---|---|---|
| Net revenue | 1,595,555 | 1,506,868 | 5.9% | 4,543,417 | 4,316,286 | 5.3% |
| Net income | 135,555 | 74,599 | 81.7% | 213,613 | 193,384 | 10.5% |
| Adjusted EBITDA(1) | 356,557 | 342,119 | 4.2% | 946,145 | 942,753 | 0.4% |
Income Statement
Range for the year ending — GMR is updating the following guidance for the full year 2026: (in millions)
| Range for the year ending – December 31, 2026 – Low | Range for the year ending – December 31, 2026 – High | |
|---|---|---|
| Net revenue | 5,900 | 6,050 |
| Adjusted EBITDA(2) | 1,135 | 1,195 |
| Cash used for net capital expenditures and aircraft financing as a percent of net revenue | 5.2% | 5.4% |
Income Statement
Three Months Ended — )
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | |
|---|---|---|---|---|
| Net revenue | 1,595,555 | 1,506,868 | 4,543,417 | 4,316,286 |
| Operating expenses: | ||||
| Employee wages, benefits and taxes | 801,712 | 773,658 | 2,496,240 | 2,251,033 |
| Maintenance, fuel and other direct expenses | 150,034 | 119,922 | 405,071 | 344,350 |
| Insurance expense | 55,186 | 57,214 | 149,042 | 142,167 |
| Other operating expenses | 238,390 | 225,158 | 698,384 | 661,872 |
| Depreciation and amortization | 78,531 | 73,366 | 230,854 | 221,000 |
| Impairment of assets held for sale and other investments | 14,100 | |||
| Acquisition, integration and other charges | 10,231 | 40,976 | 26,768 | 46,332 |
| Total operating expenses | 1,334,084 | 1,290,294 | 4,006,359 | 3,680,854 |
| Operating income | 261,471 | 216,574 | 537,058 | 635,432 |
| Interest expense, net | 68,062 | 107,205 | 228,084 | 329,406 |
| Loss on debt extinguishment | 5,745 | 5,745 | ||
| Equity in (earnings) losses of unconsolidated affiliates | -1,272 | -226 | -2,171 | -2,800 |
| Other (income) loss, net | 220 | -635 | -6,549 | 8,911 |
| Net income (loss) before income taxes | 194,461 | 104,485 | 317,694 | 294,170 |
| Income tax (benefit) expense | 58,906 | 29,886 | 104,081 | 100,786 |
| Net income (loss) | 135,555 | 74,599 | 213,613 | 193,384 |
| Net income (loss) available to common stockholders per share: | ||||
| Basic | 1.69 | 0.22 | 0.99 | 1.06 |
| Diluted | 0.56 | 0.07 | 0.31 | 0.32 |
| Weighted-average common shares outstanding: | ||||
| Basic | 80,102,050 | 45,553,968 | 62,997,926 | 45,553,313 |
| Diluted | 242,376,462 | 148,330,947 | 200,337,433 | 148,619,004 |
| Comprehensive income (loss): | ||||
| Net income (loss) | 135,555 | 74,599 | 213,613 | 193,384 |
| Other comprehensive income (loss) | ||||
| Unrealized holding gains (losses) on investments | -1,734 | 685 | -1,421 | 1,524 |
| Deferred income tax benefit (expense), net | 385 | -151 | 315 | -337 |
| Total other comprehensive income (loss), net of income tax | -1,349 | 534 | -1,106 | 1,187 |
| Comprehensive income (loss) | 134,206 | 75,133 | 212,507 | 194,571 |
Income Statement
Three Months Ended — The following table reconciles net income to EBITDA and Adjusted EBITDA:
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | 2026 v. – 2025 Change | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | 2026 v. – 2025 Change | |
|---|---|---|---|---|---|---|
| Net income (loss) | 135,555 | 74,599 | 81.7 | 213,613 | 193,384 | 10.5 |
| Interest expense, net | 68,062 | 107,205 | -36.5 | 228,084 | 329,406 | -30.8 |
| Income tax provision (benefit) | 58,906 | 29,886 | 97.1 | 104,081 | 100,786 | 3.3 |
| Depreciation and amortization | 78,531 | 73,366 | 7 | 230,854 | 221,000 | 4.5 |
| EBITDA | 341,054 | 285,056 | 19.6 | 776,632 | 844,576 | -8 |
| Management fees(1) | 2,705 | nm | 4,721 | 8,116 | -41.8 | |
| Stock-based compensation(2) | 1,551 | 5,762 | -73.1 | 134,062 | 11,353 | 1,080.9 |
| Professional fees and other expenses for non-recurring matters(3) | 11,481 | 4,492 | 155.6 | 34,627 | 11,867 | 191.8 |
| Debt refinancing fees paid to (received from) third parties(4) | 3,362 | 39,098 | -91.4 | 3,921 | 39,470 | -90.1 |
| Impairment of assets held for sale and other investments(5) | nm | 14,100 | nm | |||
| Loss on debt extinguishment(6) | 5,745 | nm | 5,745 | nm | ||
| (Gain) loss on divestiture of businesses(7) | nm | 3,837 | nm | |||
| Realized and unrealized (gain) loss, net(8) | 381 | -513 | -174.3 | -5,647 | 6,489 | -187 |
| Equity method investment (income) loss(9) | -1,272 | -226 | 462.8 | -2,171 | -2,800 | -22.5 |
| Adjusted EBITDA | 356,557 | 342,119 | 4.2 | 946,145 | 942,753 | 0.4 |
Income Statement
Three Months Ended — (Unaudited)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | |
|---|---|---|---|---|
| Diluted net income (loss) available to common stockholders per share (GAAP) | 0.56 | 0.07 | 0.31 | 0.32 |
| Undeclared dividends on redeemable preferred stock(3) | 0.27 | 0.16 | 0.81 | |
| Loss on redemption of redeemable preferred stock(3) | 0.16 | 0.59 | 0.16 | |
| Management fees(4) | 0.02 | 0.02 | 0.05 | |
| Stock-based compensation(4) | 0.01 | 0.04 | 0.67 | 0.08 |
| Professional fees and other expenses for non-recurring matters(4) | 0.05 | 0.03 | 0.17 | 0.08 |
| Debt refinancing fees paid to (received from) third parties(4) | 0.01 | 0.26 | 0.02 | 0.27 |
Balance Sheet
September 30, — (Amounts in thousands, except share and par value amounts)
| September 30, – 2026 – (unaudited) | December 31, – 2025 | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 297,987 | 609,349 |
| Insurance collateral | 85,472 | 78,608 |
| Accounts receivable, net | 1,249,293 | 1,094,814 |
| Spare parts, medical supplies and fuel | 128,877 | 115,725 |
| Prepaid expenses | 88,040 | 105,014 |
| Reinsurance recoverables | 112,711 | 81,791 |
| Other current assets | 53,937 | 46,780 |
| Total current assets | 2,016,317 | 2,132,081 |
| Property and equipment, net of accumulated depreciation of $1,351,267 and $1,223,603 at September 30, 2026 and December 31, 2025, respectively | 1,462,548 | 1,361,278 |
| Operating right-of-use assets | 224,519 | 203,258 |
| Finance right-of-use assets | 77,046 | 85,030 |
| Intangible assets, net | 1,155,838 | 1,204,237 |
| Goodwill | 2,180,581 | 2,180,581 |
| Other assets | 403,499 | 315,580 |
| Total assets | 7,520,348 | 7,482,045 |
| Current liabilities: | ||
| Accounts payable | 66,259 | 60,047 |
| Accrued wages, benefits and taxes | 299,660 | 339,710 |
| Accrued interest | 38,713 | 75,655 |
| Other accrued liabilities | 510,762 | 363,160 |
| Current portion of lease obligations | 76,138 | 78,717 |
| Current portion of long-term debt | 164,104 | 147,140 |
| Total current liabilities | 1,155,636 | 1,064,429 |
| Operating lease obligations | 193,227 | 171,880 |
| Finance lease obligations | 74,359 | 74,943 |
| Long-term debt | 4,096,043 | 4,898,769 |
| Deferred income taxes | 208,740 | 209,067 |
| Tax receivable agreement liability | 470,791 | |
| Insurance reserves | 362,664 | 312,069 |
| Other long-term liabilities | 50,619 | 101,593 |
| Total liabilities | 6,612,079 | 6,832,750 |
| Mezzanine equity: | ||
| Redeemable preferred stock | 445,140 | |
| Total mezzanine equity | 445,140 | |
| Stockholders’ equity: | ||
| Class A Common stock, $0.0001 par value, 1,200,000,000 and 200,000,000 shares authorized, 66,698,468 and 22,096,835 shares issued and outstanding, respectively, as of September 30, 2026 and December 31, 2025 | 7 | 2 |
| Additional paid-in capital | 948,068 | 456,466 |
| Retained earnings (deficit) | -45,879 | -259,492 |
| Accumulated other comprehensive income (loss) | 6,073 | 7,179 |
| Total stockholders' equity (deficit) | 908,269 | 204,155 |
| Total liabilities, mezzanine equity and stockholders' equity | 7,520,348 | 7,482,045 |
Cash Flow
Nine Months Ended — (Amounts in thousands, unaudited)
| Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income (loss) | 213,613 | 193,384 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities | ||
| Depreciation and amortization | 230,854 | 221,000 |
| Amortization of deferred financing costs and debt discount | 18,134 | 11,236 |
| Paid-in-kind interest on long-term debt | 22,450 | |
| Loss on debt extinguishment | 5,745 | |
| Impairment of assets held for sale and other investments | 14,100 | |
| (Gain) loss on divestiture of businesses | 3,837 | |
| Stock-based compensation expense | 142,640 | 1,796 |
| Liability classified stock awards | -11,569 | 9,557 |
| Loss (gain) on disposal of property and equipment | 1,822 | 8,435 |
| Unrealized loss (gain) on marketable equity securities | 1,298 | 270 |
| Deferred income taxes | -12 | -7 |
| Other, net | -9,071 | 3,419 |
| Changes in assets and liabilities, net of effects of acquisitions | ||
| Accounts receivable, net | -154,479 | -112,187 |
| Accounts payable | 6,212 | 3,340 |
| Accrued wages, benefits and taxes | -40,678 | 26,983 |
| Accrued interest | -36,942 | -5,930 |
| Accrued liabilities | 84,041 | -50,216 |
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts, including statements related to momentum in Nurse Navigation, market growth and our financial guidance. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, you can identify these forward-looking statements by the use of words such as “anticipate,” “assume,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “future,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would,” the negative version of these words, or similar terms and phrases.³
... (truncated)believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:⁴
These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and in our filings with the SEC, including the information under the caption “Risk Factors” in GMR’s final prospectus (the “IPO Prospectus”) in connection with our initial public offering (the “IPO”), filed with the SEC and dated May 12, 2026, as well as GMR’s subsequent other filings with the SEC from time to time. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements.
Any forward-looking statement made by us herein speaks only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included herein. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. For additional information on these and other factors that could cause GMR’s actual results to differ materially from expected results, please see our filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and on the “Investor Relations” tab of our website.
Non-GAAP Financial Measures
This press release contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with GAAP. Specifically, we make use of the non-GAAP financial measures “EBITDA,” “Adjusted EBITDA,” and “Adjusted Diluted EPS.”
We provide non-GAAP financial information to enhance the understanding of our GAAP financial information and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure is presented along with the corresponding GAAP measure so as not to imply that more emphasis should be placed on the non-GAAP measure. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess performance. The non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies.
EBITDA and Adjusted EBITDA
We define EBITDA as net income (loss) before interest expense, net, income tax provision (benefit), and depreciation and amortization. We define Adjusted EBITDA as EBITDA, as further adjusted to exclude management fees, stock-based compensation, professional fees and other expenses for non-recurring matters, debt refinancing fees paid to (received from) third parties and certain other items that we do not consider indicative of our ongoing operating performance.
Management uses EBITDA and Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, to report compliance with certain covenants in our debt agreements and to compare our performance against that of peer companies using similar measures. Moreover, we present EBITDA and Adjusted EBITDA because we believe that investors consider them to be important supplemental measures of our performance and believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry.
⁵
Adjusted EBITDA is an analytical indicator used by management and the healthcare industry to evaluate company performance and allocate resources. Adjusted EBITDA should not be considered in isolation or as an alternative to net income (loss), cash flows from operations, investing or financing activities, or other financial statement data presented in the unaudited condensed consolidated financial statements as indicators of financial performance. Because Adjusted EBITDA is not a measure determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies and may not be comparable to similarly titled measures used in debt compliance calculations. Net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most comparable to Adjusted EBITDA, as defined.
Adjusted Diluted EPS
... (truncated)the inclusion of potentially dilutive stock awards and warrants excluded from GAAP diluted shares due to a net loss position, but do not include stock awards or warrants that are out of the money and whose inclusion would be antidilutive. We believe Adjusted Diluted EPS is useful to investors because it facilitates period-to-period comparisons of our earnings performance by excluding the effects of our pre-IPO preferred stock and other items that we do not consider indicative of our ongoing operating performance.
GMR Contacts:
Media Contact:
Kirsten Gurmendi
Public Relations Director, GMR Solutions Inc. media@gmr.net
877.418.2980
Investor Contact:
Krister Sorensen
Vice President, Investor Relations, GMR Solutions Inc.
Investor.relations@gmr.net
⁶
GMR Solutions Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
September 30, 2026 and December 31, 2025
(Amounts in thousands, except share and par value amounts)
⁷
GMR Solutions Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
For the three and nine months ended September 30, 2026 and 2025
(
Amounts in thousands, except share and per share amounts, unaudited)
⁸
GMR Solutions Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
For the nine months ended September 30, 2026 and 2025
(Amounts in thousands, unaudited)
⁹
GMR Solutions Inc. and Subsidiaries
Reconciliation of EBITDA and Adjusted EBITDA
For the three and nine months ended September 30, 2026 and 2025
(Amounts in thousands, unaudited)
The following table reconciles net income to EBITDA and Adjusted EBITDA:
nm – Not meaningful
¹⁰
¹¹
GMR Solutions Inc. and Subsidiaries
Reconciliation of Weighted-Average Common Shares Outstanding Used in Diluted EPS and Adjusted Diluted EPS
(Unaudited)
Reconciliation of Diluted Net Income (Loss) Available to Common Stockholders per Share to Adjusted Diluted EPS
(Unaudited)
¹²
¹³